449 related articles for article (PubMed ID: 26708265)
1. Killing effect of nanoencapsulated colistin sulfate on Pseudomonas aeruginosa from cystic fibrosis patients.
Sans-Serramitjana E; Fusté E; Martínez-Garriga B; Merlos A; Pastor M; Pedraz JL; Esquisabel A; Bachiller D; Vinuesa T; Viñas M
J Cyst Fibros; 2016 Sep; 15(5):611-8. PubMed ID: 26708265
[TBL] [Abstract][Full Text] [Related]
2. Determination of the spatiotemporal dependence of
Sans-Serramitjana E; Jorba M; Pedraz JL; Vinuesa T; Viñas M
Int J Nanomedicine; 2017; 12():4409-4413. PubMed ID: 28652741
[TBL] [Abstract][Full Text] [Related]
3. Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience.
Hansen CR; Pressler T; Høiby N
J Cyst Fibros; 2008 Nov; 7(6):523-30. PubMed ID: 18693078
[TBL] [Abstract][Full Text] [Related]
4. In vivo pharmacokinetics/pharmacodynamics of colistin and imipenem in Pseudomonas aeruginosa biofilm infection.
Hengzhuang W; Wu H; Ciofu O; Song Z; Høiby N
Antimicrob Agents Chemother; 2012 May; 56(5):2683-90. PubMed ID: 22354300
[TBL] [Abstract][Full Text] [Related]
5. Optimization of colistin dosing regimen for cystic fibrosis patients with chronic Pseudomonas aeruginosa biofilm lung infections.
Hengzhuang W; Green K; Pressler T; Skov M; Katzenstein TL; Wu X; Høiby N
Pediatr Pulmonol; 2019 May; 54(5):575-580. PubMed ID: 30803159
[TBL] [Abstract][Full Text] [Related]
6. A Low-Molecular-Weight Alginate Oligosaccharide Disrupts Pseudomonal Microcolony Formation and Enhances Antibiotic Effectiveness.
Pritchard MF; Powell LC; Jack AA; Powell K; Beck K; Florance H; Forton J; Rye PD; Dessen A; Hill KE; Thomas DW
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630204
[TBL] [Abstract][Full Text] [Related]
7. In vitro activity of colistin against biofilm by Pseudomonas aeruginosa is significantly improved under "cystic fibrosis-like" physicochemical conditions.
Pompilio A; Crocetta V; Pomponio S; Fiscarelli E; Di Bonaventura G
Diagn Microbiol Infect Dis; 2015 Aug; 82(4):318-25. PubMed ID: 26004353
[TBL] [Abstract][Full Text] [Related]
8. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis.
Waters V; Ratjen F
Cochrane Database Syst Rev; 2012 Nov; 11():CD009528. PubMed ID: 23152277
[TBL] [Abstract][Full Text] [Related]
9. Novel Inhaled Combination Powder Containing Amorphous Colistin and Crystalline Rifapentine with Enhanced Antimicrobial Activities against Planktonic Cells and Biofilm of Pseudomonas aeruginosa for Respiratory Infections.
Zhou QT; Sun SP; Chan JG; Wang P; Barraud N; Rice SA; Wang J; Li J; Chan HK
Mol Pharm; 2015 Aug; 12(8):2594-603. PubMed ID: 25423590
[TBL] [Abstract][Full Text] [Related]
10. Antimicrobial resistance, respiratory tract infections and role of biofilms in lung infections in cystic fibrosis patients.
Ciofu O; Tolker-Nielsen T; Jensen PØ; Wang H; Høiby N
Adv Drug Deliv Rev; 2015 May; 85():7-23. PubMed ID: 25477303
[TBL] [Abstract][Full Text] [Related]
11. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis.
Waters V; Ratjen F
Cochrane Database Syst Rev; 2015 Mar; (3):CD009528. PubMed ID: 25741986
[TBL] [Abstract][Full Text] [Related]
12. Free and Nanoencapsulated Tobramycin: Effects on Planktonic and Biofilm Forms of Pseudomonas.
Sans-Serramitjana E; Jorba M; Fusté E; Pedraz JL; Vinuesa T; Viñas M
Microorganisms; 2017 Jun; 5(3):. PubMed ID: 28672861
[TBL] [Abstract][Full Text] [Related]
13. Phenotypic shift in Pseudomonas aeruginosa populations from cystic fibrosis lungs after 2-week antipseudomonal treatment.
Fernández-Barat L; Ciofu O; Kragh KN; Pressler T; Johansen U; Motos A; Torres A; Hoiby N
J Cyst Fibros; 2017 Mar; 16(2):222-229. PubMed ID: 27651273
[TBL] [Abstract][Full Text] [Related]
14. Impairment of Pseudomonas aeruginosa Biofilm Resistance to Antibiotics by Combining the Drugs with a New Quorum-Sensing Inhibitor.
Furiga A; Lajoie B; El Hage S; Baziard G; Roques C
Antimicrob Agents Chemother; 2015 Dec; 60(3):1676-86. PubMed ID: 26711774
[TBL] [Abstract][Full Text] [Related]
15. Sodium colistimethate loaded lipid nanocarriers for the treatment of Pseudomonas aeruginosa infections associated with cystic fibrosis.
Pastor M; Moreno-Sastre M; Esquisabel A; Sans E; Viñas M; Bachiller D; Asensio VJ; Pozo AD; Gainza E; Pedraz JL
Int J Pharm; 2014 Dec; 477(1-2):485-94. PubMed ID: 25445528
[TBL] [Abstract][Full Text] [Related]
16. Early eradication therapy against Pseudomonas aeruginosa in cystic fibrosis patients.
Taccetti G; Campana S; Festini F; Mascherini M; Döring G
Eur Respir J; 2005 Sep; 26(3):458-61. PubMed ID: 16135728
[TBL] [Abstract][Full Text] [Related]
17. Colistin-tobramycin combinations are superior to monotherapy concerning the killing of biofilm Pseudomonas aeruginosa.
Herrmann G; Yang L; Wu H; Song Z; Wang H; Høiby N; Ulrich M; Molin S; Riethmüller J; Döring G
J Infect Dis; 2010 Nov; 202(10):1585-92. PubMed ID: 20942647
[TBL] [Abstract][Full Text] [Related]
18. In vitro prevention of Pseudomonas aeruginosa early biofilm formation with antibiotics used in cystic fibrosis patients.
Fernández-Olmos A; García-Castillo M; Maiz L; Lamas A; Baquero F; Cantón R
Int J Antimicrob Agents; 2012 Aug; 40(2):173-6. PubMed ID: 22727530
[TBL] [Abstract][Full Text] [Related]
19. Increased bactericidal activity of colistin on Pseudomonas aeruginosa biofilms in anaerobic conditions.
Kolpen M; Appeldorff CF; Brandt S; Mousavi N; Kragh KN; Aydogan S; Uppal HA; Bjarnsholt T; Ciofu O; Høiby N; Jensen PØ
Pathog Dis; 2016 Feb; 74(1):ftv086. PubMed ID: 26458402
[TBL] [Abstract][Full Text] [Related]
20. Activity of colistin combined with doripenem at clinically relevant concentrations against multidrug-resistant Pseudomonas aeruginosa in an in vitro dynamic biofilm model.
Lora-Tamayo J; Murillo O; Bergen PJ; Nation RL; Poudyal A; Luo X; Yu HY; Ariza J; Li J
J Antimicrob Chemother; 2014 Sep; 69(9):2434-42. PubMed ID: 24833752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
